128 related articles for article (PubMed ID: 7807185)
1. Immunotoxin therapy of leptomeningeal neoplasia.
Walbridge S; Rybak SM
J Neurooncol; 1994; 20(1):59-65. PubMed ID: 7807185
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia.
Zovickian J; Youle RJ
J Neurosurg; 1988 May; 68(5):767-74. PubMed ID: 3258632
[TBL] [Abstract][Full Text] [Related]
3. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
Gregg EO; Bridges SH; Youle RJ; Longo DL; Houston LL; Glennie MJ; Stevenson FK; Green I
J Immunol; 1987 Jun; 138(12):4502-8. PubMed ID: 3495593
[TBL] [Abstract][Full Text] [Related]
4. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
[TBL] [Abstract][Full Text] [Related]
5. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
6. Intraventricular immunotoxin therapy for leptomeningeal neoplasia.
Laske DW; Muraszko KM; Oldfield EH; DeVroom HL; Sung C; Dedrick RL; Simon TR; Colandrea J; Copeland C; Katz D; Greenfield L; Groves ES; Houston LL; Youle RJ
Neurosurgery; 1997 Nov; 41(5):1039-49; discussion 1049-51. PubMed ID: 9361057
[TBL] [Abstract][Full Text] [Related]
7. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract][Full Text] [Related]
8. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
10. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
11. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
[TBL] [Abstract][Full Text] [Related]
13. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
14. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
15. Mouse multivalent IgG(2a, b) antibody--ricin A-chain immunotoxins combined with homologous or heterologous interleukin 2 in the treatment of a murine malignant lymphoproliferation (EL4).
Mota G; Marches R; Cialacu V; Roman V; Kozma E; Mărgineanu M; Dima S; Moraru II
Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):131-6. PubMed ID: 8915518
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin.
Herrlinger U; Schmidberger H; Buchholz R; Wehrmann M; Vallera DA; Schabet M
J Neurooncol; 1998 Oct; 40(1):1-9. PubMed ID: 9874180
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of an antibody-ricin conjugate administered intraperitoneally to mice.
Brusa P; Dosio F; Pacchioni D; Delprino L; Grosa G; Bussolati G; Cattel L
J Pharm Sci; 1994 Apr; 83(4):514-9. PubMed ID: 8046606
[TBL] [Abstract][Full Text] [Related]
18. Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL.
Mischak RP; Foxall C; Rosendorf LL; Knebel K; Scannon PJ; Spitler LE
Mol Biother; 1990 Jun; 2(2):104-9. PubMed ID: 2363853
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of fresh leukemic cells to T101 ricin A-chain immunotoxin: a comparative study between Fab fragment and whole Ig conjugates.
Chiron M; Derocq JM; Kuhlein E; Roubinet F; Demur C; Grandjean H; Huguet F; Jaffrezou JP; Jansen F; Laurent G
Leuk Res; 1989; 13(6):491-9. PubMed ID: 2788783
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
